A hydrolyzed peptide of recombinant collagen, preparation method and use thereof
By catalyzing recombinant collagen hydrolysis by specific endopeptidases, the fragment inactivation and sensitization risks in the collagen hydrolyzed peptide extraction method were solved, and a biologically active hydrolyzed peptide was prepared for cosmetics, medical beauty and biomedical fields. It achieves cell proliferation, antioxidant and moisturizing effects.
Patent Information
- Application Number
- CN202310232836.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-13
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2043-03-13
AI Technical Summary
The existing collagen hydrolytic peptide extraction methods have a large number of fragment inactivation, irregular amino acid sequence and length, risk of sensitization of extracts from animal sources and risk of virus carrying, which limits its industrial production and application.
A specific endopeptidase is used to hydrolyze the recombinant collagen to obtain a hydrolyzed peptide with a specific amino acid sequence and length, and protease catalyzed under suitable conditions to prepare a hydrolyzed peptide with biological activity.
It realizes the biological activity of hydrolyzed peptides, promotes cell proliferation and migration, has repair, antioxidant, moisturizing and moisturizing effects, and is suitable for health care products, cosmetics, medical beauty products and biomedical fields.
Smart Images

Figure BDA0004120966020000051 
Figure BDA0004120966020000061 
Figure BDA0004120966020000091
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of gene engineering technology, and specifically relates to a hydrolyzed peptide of a recombinant collagen-like protein having an amino acid sequence as shown in SEQ ID NO: 1, a preparation method thereof, and uses thereof. Background Art
[0002] Collagen is the most common protein in mammals, accounting for about 30% of the total protein. So far, scientists from various countries have discovered and identified at least 28 types of collagen. As a structural protein, collagen is widely present in skin, connective tissue and bones. It plays an important role in maintaining the extracellular environment, maintaining the physiological functions of tissues and organs, and repairing damage. Compared with artificially synthesized polymer materials, collagen has good biocompatibility and degradability. Therefore, collagen is widely used in health care products, cosmetics, medical beauty and other industries.
[0003] Natural collagen has a complex and characteristic triple helix structure, which is formed by three polypeptide chains connected by interchain hydrogen bonds. The triple helix structure is a left-handed helix with three amino acid residues as the basic repeating sequence, and these three amino acids are usually Gly-XY. At the same time, the organism modifies collagen in a complex way through a complex enzymatic system, and the unmodified polypeptide chain will not be able to form a correct triple helix structure, thus lacking the biological function that collagen should have. However, as a high-molecular substance with a relatively complex structure, natural collagen is usually insoluble in water, and it is not easy to penetrate the surface of the skin to reach the part where it exerts its biological function - the basal layer of the skin; it usually needs to be treated by chemical means before it can be used by the human body. The traditional method of producing collagen is to use acid and alkali digestion of tissues such as bones and skin of pigs, horses, cattle, chickens or fish to obtain hydrolyzed collagen peptides. The molecular weight of hydrolyzed collagen peptides is generally less than 10kDa, and its water solubility and permeability are significantly improved compared with natural collagen. At the same time, a small number of hydrolyzed collagen peptides that retain functional segments still have the biological functions of natural collagen.
[0004] However, the hydrolyzed collagen peptides obtained by the above method also have obvious technical defects. Most of the fragments have been inactivated and cannot exert their biological functions, resulting in a large amount of material waste. Secondly, the chemical digestion method generally randomly hydrolyzes peptide bonds, resulting in the amino acid sequence and length of the resulting product being not fixed and unable to be accurately controlled. In addition, the instability between animal batches exacerbates the volatility of the quality of hydrolyzed collagen peptides between batches, resulting in the inability to standardize industrial production on a large scale. Third, collagen extracted from other animals is not compatible with the human body and has a greater risk of allergenicity and even immune rejection. Finally, the risk of virus carrying in animal-derived extracts is also difficult to avoid. In short, the application of hydrolyzed collagen peptides extracted from animal tissues is also relatively limited.
[0005] Protease is a general term for a class of enzymes that can catalyze the hydrolysis of protein peptide bonds. According to the recognition site and mode of action, proteases can be divided into exopeptidases and endopeptidases. Exopeptidases have low selectivity for amino acid residues and can hydrolyze peptide bonds one by one from the free amino terminus or free carboxyl terminus of the protease to release free amino acids. Endopeptidases have high substrate selectivity and can recognize and hydrolyze peptide bonds formed by one or a class of specific amino acids. By using specific endopeptidases to catalyze the hydrolysis of collagen of known sequence, hydrolyzed collagen peptides of specific sequence can be obtained, which ensures the repeatability of the amino acid sequence and length of the hydrolyzed collagen peptides. Therefore, the art needs a technical solution for preparing bioactive hydrolyzed collagen peptides based on protease biocatalysis. Summary of the invention
[0006] The present invention uses a recombinant collagen protein with an amino acid sequence as shown in SEQ ID NO: 1 as a substrate, and hydrolyzes it with a protease to obtain a hydrolyzed peptide. The hydrolyzed peptide can promote cell proliferation and migration, and also has the effects of repair, anti-oxidation, and moisturizing. When the hydrolyzed peptide is used in combination with appropriate raw materials and auxiliary materials, it can be made into health products, cosmetics, medical beauty products, etc.
[0007] The present disclosure provides a hydrolyzed peptide of a recombinant collagen-like protein, wherein the amino acid sequence of the recombinant collagen-like protein is shown as SEQ ID NO: 1.
[0008] The present disclosure also provides a polynucleotide encoding the recombinant collagen-like protein of the present disclosure whose amino acid sequence is shown in SEQ ID NO: 1. In some embodiments, the sequence of the polynucleotide is shown in SEQ ID NO: 2.
[0009] The present disclosure also provides a recombinant collagen-like protein, whose amino acid sequence is shown in SEQ ID NO: 1.
[0010] In some embodiments, the hydrolyzed peptide is obtained by hydrolyzing a recombinant collagen-like protein with an amino acid sequence as shown in SEQ ID NO: 1 under the action of a protease. In some embodiments, the protease is an intracellular protease. In some embodiments, the intracellular protease is a recombinant lysyl endonuclease. In some embodiments, the hydrolyzed peptide is obtained by hydrolyzing a recombinant collagen protein having an amino acid sequence as shown in SEQ ID NO: 1 under the action of an intracellular protease, and the mass concentration of the substrate and the intracellular protease at the start of the hydrolysis reaction is selected from 1:50-2000, preferably 1:100, 1:200, 1:300, 1:400, 1:500, 1:600, 1:700, 1:800, 1:900, 1:1000, 1:1100, 1:1200, 1:1300, 1:1400, 1:1500, 1:1600, 1:1700, 1:1800, 1:1900, 1:2000.
[0011] In some embodiments, the hydrolytic peptide is LC1, which is a recombinant collagen-like protein with an amino acid sequence as shown in SEQ ID NO: 1 and an intracellular protease mixed at a protein mass concentration ratio of 1: 100, hydrolyzed at 28 ° C, pH = 7.0 (50mM Tris-HCl) for 16 hours, and inactivated at 95 ° C. In some embodiments, the hydrolytic peptide is LC2, which is a recombinant collagen-like protein with an amino acid sequence as shown in SEQ ID NO: 1 and an intracellular protease mixed at a protein mass concentration ratio of 1: 500, hydrolyzed at 30 ° C, pH = 8.0 (100mM Tris-HCl) for 12 hours, and inactivated at 95 ° C. In some embodiments, the hydrolytic peptide is LC3, which is a recombinant collagen-like protein with an amino acid sequence as shown in SEQ ID NO: 1 and an intracellular protease mixed at a protein mass concentration ratio of 1: 800, hydrolyzed at 37 ° C, pH = 8.5 (100mM Tris-HCl) for 8 hours, and inactivated at 95 ° C. In some embodiments, the hydrolyzed peptide is LC4, which is obtained by mixing a recombinant collagen-like protein with an amino acid sequence as shown in SEQ ID NO: 1 and an intracellular protease at a protein mass concentration ratio of 1:1500, hydrolyzing at 42°C, pH = 7.5 (50mM Tris-HCl) for 2h, and inactivating at 95°C.
[0012] The present disclosure also provides the use of hydrolyzed peptides of recombinant collagen-like proteins with amino acid sequences such as those shown in SEQ ID NO:1 in the preparation of anti-aging products. The present disclosure also provides the use of hydrolyzed peptides of recombinant collagen-like proteins with amino acid sequences such as those shown in SEQ ID NO:1 in the preparation of repair products. The present disclosure also provides the use of hydrolyzed peptides of recombinant collagen-like proteins with amino acid sequences such as those shown in SEQ ID NO:1 in the preparation of antioxidant products. The present disclosure also provides the use of hydrolyzed peptides of recombinant collagen-like proteins with amino acid sequences such as those shown in SEQ ID NO:1 in the preparation of hydrating and moisturizing products.
[0013] The present disclosure also provides a method for preparing a hydrolyzed peptide of a recombinant collagen-like protein having an amino acid sequence as shown in SEQ ID NO: 1, comprising mixing a recombinant collagen-like protein having a substrate amino acid sequence as shown in SEQ ID NO: 1 with a protease, reacting under suitable temperature and suitable pH conditions, and inactivating. In some embodiments, the protease is an intracellular protease. In some embodiments, the intracellular protease is a recombinant lysyl endonuclease protease. In some embodiments, the suitable temperature is selected from 20°C to 45°C, preferably 25°C to 45°C, more preferably 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, 36°C, 37°C, 38°C, 39°C, 40°C, 41°C, 42°C. In some embodiments, the suitable pH is selected from 6.5 to 9.0, preferably 7.0 to 8.5, more preferably 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5. In some embodiments, the reaction is carried out for 2 to 40 hours, preferably 2 to 20 hours, more preferably 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours. In some embodiments, the inactivation in the preparation method is carried out at 95°C. In some embodiments, the preparation method includes: mixing the substrate and the intracellular protease at a protein mass concentration ratio of 1:100, hydrolyzing at 28°C, pH=7.0 (50mM Tris-HCl) for 16 hours, and inactivating at 95°C to obtain the hydrolyzed peptide LC1. In some embodiments, the preparation method includes: mixing the substrate and the intracellular protease at a protein mass concentration ratio of 1:500, hydrolyzing at 30°C, pH=8.0 (100mM Tris-HCl) for 12 hours, and inactivating at 95°C to obtain the hydrolyzed peptide LC2. In some embodiments, the preparation method includes: mixing the substrate and the intracellular protease at a protein mass concentration ratio of 1:800, hydrolyzing at 37°C, pH=8.5 (100mM Tris-HCl) for 8 hours, and inactivating at 95°C to obtain the hydrolyzed peptide LC3. In some embodiments, the preparation method comprises: mixing the substrate and the intracellular protease at a protein mass concentration ratio of 1:1500, hydrolyzing at 42°C, pH=7.5 (50mM Tris-HCl) for 2h, and inactivating at 95°C to obtain the hydrolyzed peptide LC4.
[0014] The present disclosure also provides the use of the hydrolyzed peptide of the recombinant collagen-like protein with an amino acid sequence as shown in SEQ ID NO: 1 in the preparation of biomedical products, sponge-like materials, fibers, gel-like materials and film-like materials. Biomedical products, such as skin implants, drug carriers, plastic coatings for medical devices, implant coatings (plastic surgery and blood vessels), molding materials, mucous surgery, vascular sealants, cosmetics and enzyme activity regulators (such as metalloproteinases); sponge-like materials, such as three-dimensional cell culture, tissue and organ engineering, hemostatic agents and wound treatment (artificial skin and wound dressings); fibers, such as surgical sutures and hemostatic agents; gel-like materials, such as tissue implants, corneal shields, contact lenses and cell culture matrices; and film-like materials, such as anti-adhesion membranes, drug delivery systems, artificial skin, etc. In addition, the hydrolyzed peptide of the recombinant collagen-like protein with an amino acid sequence as shown in SEQ ID NO: 1 can be used for industrial applications outside the biomedical field, including but not limited to the following: leather industry applications, stabilizers, thickeners in glue manufacturing, emulsifiers, foaming agents suitable for paper or textile manufacturing, photographic films, the manufacture of rubber substitutes, food industry applications, etc.
[0015] The present disclosure also provides the use of a hydrolyzed peptide of a recombinant collagen-like protein having an amino acid sequence as shown in SEQ ID NO: 1 in the preparation of health products, cosmetics, and medical beauty products.
[0016] Cell proliferation and migration are the basis of physiological processes such as anti-inflammation, coagulation, wound healing, and angiogenesis. Based on the cell proliferation and migration promoting activity of the hydrolyzed peptide of the recombinant collagen-like protein with the amino acid sequence of SEQ ID NO: 1 disclosed in the present invention, the hydrolyzed peptide of the recombinant collagen-like protein with the amino acid sequence of SEQ ID NO: 1 disclosed in the present invention can be used in the fields of cosmetics, health products, and medical beauty products. The hydrolyzed peptide disclosed in the present invention has the effect of moisturizing and moisturizing, can replenish the moisture required by the stratum corneum cells of the skin, moisturize the skin, and can prevent the evaporation of skin moisture, improve microcirculation, and increase the moisture content of the skin. Therefore, the hydrolyzed peptide disclosed in the present invention can be used in the fields of cosmetics, health products, and medical beauty products. Further, the hydrolyzed peptide of the recombinant collagen-like protein with the amino acid sequence of SEQ ID NO: 1 disclosed in the present invention also has antioxidant activity, can play a beneficial role in antioxidant and anti-aging, and further broadens the application of the hydrolyzed peptide disclosed in the fields of cosmetics, health products, and medical beauty products. Furthermore, the hydrolyzed peptides of the recombinant collagen-like protein with an amino acid sequence as shown in SEQ ID NO: 1 disclosed in the present invention also have repair and maintenance activities, and can play a beneficial role in inhibiting cell inflammation and inflammatory infiltration, reducing tissue permeability, and promoting wound healing, further broadening the application of the hydrolyzed peptides of the recombinant collagen-like protein with an amino acid sequence as shown in SEQ ID NO: 1 disclosed in the fields of cosmetics, health products and medical beauty products.
[0017] The present disclosure also provides a composition containing a hydrolyzed peptide of a recombinant collagen-like protein having an amino acid sequence as shown in SEQ ID NO: 1. In some embodiments, the composition is a health product, a cosmetic, a medical beauty product, or a biomedical product. In some embodiments, the composition is an anti-aging product. In some embodiments, the composition is a repair product. In some embodiments, the composition is an antioxidant product. In some embodiments, the composition is a hydrating and moisturizing product.
[0018] In some embodiments, the composition further comprises an acceptable excipient. The excipient is selected from, but not limited to, solvents, solubilizers, cosolvents, suspending agents, stabilizers, emulsifiers, thickeners, matrix materials, adhesives, antioxidants, preservatives, pH regulators, wetting agents, moisturizers, spices, propellants, pearlescent agents, surfactants, compounding agents, sweeteners, colorants, flavor enhancers and / or combinations thereof.
[0019] The medical beauty products described in this disclosure refer to products used in the field of medical beauty, which are of a different level from ordinary daily skin care products and beauty salon skin care products. Some commonly used medical beauty products include medical beauty masks, dressings, etc. The use of these products needs to be carried out by professional medical staff, or relevant guidance is required. Medical beauty products, such as dressings, can be used for dermatitis, eczema, sensitive skin, and those with impaired skin barrier function after photorejuvenation, laser beauty, fruit acid rejuvenation, etc.
[0020] In some embodiments, the cosmetics described in the present disclosure are skin cosmetics.
[0021] The present disclosure also provides an expression vector, which incorporates the polynucleotide described in the present disclosure.
[0022] The present disclosure also provides a host cell, which is transformed with the polynucleotide of the present disclosure and expresses the polynucleotide.
[0023] The present disclosure also provides a method for preparing a recombinant collagen-like protein having an amino acid sequence as shown in SEQ ID NO: 1, comprising culturing the host cell described in the present disclosure under culture conditions that produce the recombinant collagen-like protein having an amino acid sequence as shown in SEQ ID NO: 1.
[0024] Advantageous Effects of the Present Disclosure
[0025] The present disclosure provides a hydrolyzed peptide of a recombinant collagen-like protein with an amino acid sequence as shown in SEQ ID NO: 1 and a composition containing the same, the hydrolyzed peptide can promote cell migration, proliferation and adhesion, and also has the effects of repair, anti-oxidation, hydration and moisturizing. When the hydrolyzed peptide of a recombinant collagen-like protein with an amino acid sequence as shown in SEQ ID NO: 1 is used in combination with appropriate raw materials and auxiliary materials, it can be made into health products, cosmetics, medical beauty products and biomedical products. DETAILED DESCRIPTION
[0026] In order to facilitate the understanding of the present disclosure, the present disclosure will be described more comprehensively with reference to the embodiments below, and preferred embodiments of the present disclosure are given below. However, the present disclosure can be implemented in many different forms and is not limited to the embodiments described herein. The purpose of providing these embodiments is to make the understanding of the disclosure of the present disclosure more thorough and comprehensive. The raw materials described in the present disclosure, unless otherwise specified, are all commercially available products.
[0027] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present disclosure. The terms used in the specification of the present disclosure are only for the purpose of describing specific embodiments and are not intended to limit the present disclosure. The term "and / or" used herein includes any and all combinations of one or more related listed items.
[0028] Table 1. Reagents, consumables, instruments and equipment information
[0029]
[0030]
[0031] Example 1 Preparation of hydrolyzed peptides of recombinant collagen-like protein with amino acid sequence as shown in SEQ ID NO: 1
[0032] The substrate used to prepare the hydrolyzed peptide of the present disclosure is a recombinant collagen protein having an amino acid sequence as shown in SEQ ID NO: 1:
[0033] MGERGAPGEKGEGGPPGVAGPPGGSGPAGPPGPQGVKGERGSPGGPGAGGPSGREGKVGQPGPPGAPGSGGPPGAVGPPGGEGKEGPAGREGGPGAGGERGAPGEKGEGGPPGVAGPPGGSGPAGPPGPQGVKGERGSPGGPGAGGPSGREGKVGQPGPPGAPGSGGPPGAVGPPGGEGKEGPAGREGGPGAGGERGAPGEKGEGGPPGVAGPPGGSGPAGPPGPQGVKGERGSPGGPGAGGPSGREGKVGQPGPPGAPGSGGPPGAVGPPGGEGKEGPAGREGGPGAGGERGAPGEKGEGGPPGVAGPPGGSGPAGPPGPQGVKGERGSPGGPGAGGPSGREGKVGQPGPPGAPGSGGPPGAVGPPGGEGKEGPAGREGGPGAGGERGAPGEKGEGGPPGVAGPPGGSGPAGPPGPQGVKGERGSPGGPGAGGPSGREGKVGQPGPPGAPGSGGPPGAVGPPGGEGKEGPAGREGGPGAGGERGAPGEKGEGGPPGVAGPPGGSGPAGPPGPQGVKGERGSPGGPGA。
[0034] The nucleotide sequence corresponding to the recombinant collagen-like protein with the amino acid sequence shown in Seq ID No.1 is shown in Seq ID No.2:
[0035]
[0036] During preparation, the nucleic acid sequence shown in Seq ID No. 2 was synthesized by General Biotechnology Co., Ltd. (Anhui) and connected to the 3' end of the EcoRI multiple cloning site of the pPIC9K vector to obtain a recombinant plasmid. The recombinant plasmid was transformed into Escherichia coli TOP10 with reference to the experimental method of the Molecular Cloning Experiment Guide (Third Edition), and an LB medium plate containing ampicillin resistance (yeast powder 5g / L, peptone 10g / L, NaCl 10g / L, agar 15g / L, ampicillin 100ug / ml) was coated, and the grown transformants were picked and inoculated in LB liquid medium containing ampicillin resistance for overnight culture, and the plasmid was extracted using a plasmid mini-extraction kit to obtain a recombinant plasmid that can be used to transform Pichia pastoris. Referring to the Manual of Multi-copy Pichia Expression (Invitrogen, Cat. No. K1750-01), the recombinant plasmid was linearized with restriction endonuclease SacI, and then electroporated into Pichia GS115 competent cells, spread on MD plates (glucose 20g / L, YNB yeast basic nitrogen source 13.4g / L, agar 20g / L), and cultured at 30°C for 3-5 days. Positive transformants were selected to YPD plates containing different concentrations of G418 (glucose 20g / L, yeast powder 10g / L, peptone 20g / L, agar 20g / L, G4180.5-5g / L), cultured at 30°C for 3-5 days, and positive transformants that can grow at different concentrations of G418 were selected for induced expression, and the positive transformants were the recombinant strains with the required multi-copy number.
[0037] The multi-copy recombinant collagen expression strain was inoculated into YPD medium containing G418, cultured at 25-32°C and 250 rpm for 16-20 h, and then inoculated into BMGY medium (glycerol 10 g / L, yeast powder 10 g / L, peptone 20 g / L, YNB yeast basic nitrogen source 13.4 g / L, 50 mM potassium phosphate buffer, biotin 0.4 mg / L) at an inoculum of 1-10% (v / v), and continued to be cultured at 25-32°C and 250 rpm until the bacterial solution OD 600 The cells were collected by centrifugation at 5000 rpm for 10 min and then resuspended in BMMY medium (methanol 10 g / L, yeast powder 10 g / L, peptone 20 g / L, YNB yeast basic nitrogen source 13.4 g / L, 50 mM potassium phosphate buffer, biotin 0.4 mg / L) until OD 600 The expression was induced at 28-30°C and 200 rpm. The inducer was methanol with a final concentration of 0.5% (v / v) added every 24 hours. The fermentation was stopped after 48-96 hours of induction. The fermentation broth was centrifuged at high speed and the supernatant was collected for purification.
[0038] The supernatant containing the target protein treated above is precipitated and salted out with 0% to 30% ammonium sulfate, and then purified by nickel column affinity chromatography under 20 to 40 mM imidazole conditions, washed with impurities under 150 to 200 mM imidazole conditions, and eluted under 300 to 400 mM imidazole conditions. At this time, the sample purity can reach more than 70%. In order to further improve the sample purity and remove impurities such as pigments, ion exchange chromatography is used for purification, the equilibrium conditions are 50 to 100 mM NaCl, pH 5.0 to 6.5, and the elution conditions are 200 to 300 mM NaCl, pH 5.0 to 6.5. The final product is the hydrolysis substrate (recombinant collagen), which is calibrated for standby use.
[0039] Preparation method of hydrolyzed peptide LC1: substrate recombinant collagen and intracellular protease (recombinant lysyl endonuclease) are mixed according to the protein mass concentration ratio of 1:100, hydrolyzed at 28°C, pH=7.0 (50mM Tris-HCl) for 16h, inactivated at 95°C, and the obtained hydrolyzed collagen peptide is named LC1.
[0040] Preparation method of hydrolyzed peptide LC2: substrate recombinant collagen and intracellular protease (recombinant lysyl endonuclease) are mixed according to the protein mass concentration ratio of 1:500, hydrolyzed at 30°C, pH=8.0 (100mM Tris-HCl) for 12h, inactivated at 95°C, and the obtained hydrolyzed collagen peptide is named LC2.
[0041] Preparation method of hydrolyzed peptide LC3: substrate recombinant collagen and intracellular protease (recombinant lysyl endonuclease) are mixed according to the protein mass concentration ratio of 1:800, hydrolyzed at 37°C, pH=8.5 (100mM Tris-HCl) for 8h, inactivated at 95°C, and the obtained hydrolyzed collagen peptide is named LC3.
[0042] Preparation method of hydrolyzed peptide LC4: substrate recombinant collagen and intracellular protease (recombinant lysyl endonuclease) are mixed according to the protein mass concentration ratio of 1:1500, hydrolyzed at 42°C, pH=7.5 (50mM Tris-HCl) for 2h, inactivated at 95°C, and the obtained hydrolyzed collagen peptide is named LC4.
[0043] The obtained hydrolyzed peptides LC1, LC2, LC3, and LC4 were used in Examples 2-7.
[0044] Example 2 Cell proliferation promoting activity of hydrolyzed peptides
[0045] 1 Experimental methods
[0046] 1.1 Cell seeding
[0047] HSF cells in the logarithmic growth phase were taken at 0.6×10 4Cells / well were seeded in 96-well plates.
[0048] 1.2 Experimental Grouping
[0049] The experiment set up a zero adjustment group, a solvent control group, a fish skin collagen peptide (FCP, 200 μg / mL) group and an LC1 sample group. Each sample in the LC1 sample group was set at 5 concentrations (0.32, 1.6, 8, 40 and 200 μg / mL), and each group of samples was set with 5 replicates.
[0050] 1.3 Administration
[0051] After 24 h of culture, the culture medium was aspirated and the cells were rinsed once with 200 μL PBS. Then, 100 μL of serum-free culture medium containing samples was added to the sample group, 100 μL of serum-free culture medium without samples was added to the solvent control wells, and only 100 μL of serum-free culture medium without samples was added to the zeroing group without cell inoculation.
[0052] 1.4 Detection
[0053] After the cells and samples were incubated for 24 hours, 10 μL CCK8 was added to each group of 100 μL culture system under light-proof conditions, and the 96-well plate was wrapped with tin foil and incubated in a CO2 incubator for 1 hour in the dark. Refer to the instructions of the CCK8 kit and use a microplate reader to measure the absorbance at λ = 450nm. If there is a slightly turbid sample, set λ = 630nm as the reference wavelength.
[0054] 1.5 Calculation of relative cell viability
[0055] Assuming the average cell viability of the solvent control group in each drug administration group is 1.000, the relative cell viability under each concentration treatment is calculated according to the following formula:
[0056]
[0057] 1.6 Statistical methods
[0058] The experimental results were summarized and statistically analyzed using GraphPad Prism 7 software. The experimental data were expressed as mean ± standard deviation (Mean ± SD). The cell viability of each drug-treated group was compared with that of the solvent control group. P < 0.05 was statistically different, P < 0.01 was significantly statistically different, and P < 0.001 was extremely significantly statistically different.
[0059] 2 Experimental results
[0060] The activity of each group of treatments on HSF cell proliferation is shown in Table 2. LC1 has significant cell proliferation promoting activity within the test concentration range (P<0.01, P<0.001); among them, 40 μg / mL is the optimal concentration, and the cell viability is 1.52 times that of the solvent control group. The control sample FCP also has similar cell proliferation promoting activity. When the test concentration is 40 μg / mL, the cell viability is 1.31 times that of the solvent control group. Therefore, the hydrolyzed peptide disclosed in the present invention has the activity of promoting cell proliferation, indicating that the hydrolyzed peptide can be used to prepare cosmetics, health products, and medical beauty products.
[0061] Table 2 Proliferation activity of hydrolyzed peptides on HSF cells (Mean±SD, n=5)
[0062]
[0063] *: compared with the solvent control group, P < 0.05; **: compared with the solvent control group, P < 0.01; ***: compared with the solvent control group, P < 0.001.
[0064] Example 3 Cell migration promoting activity of hydrolyzed peptides
[0065] 1 Experimental methods
[0066] 1.1 Placing the cell scratch plug
[0067] Place the ibidi 2-well cell scratch insert in a 12-well plate and gently press the cell insert with tweezers to ensure that the insert adheres firmly.
[0068] 1.2 Cell seeding
[0069] Take HaCaT cells in the logarithmic growth phase and dilute the cell number to 3×10 5 / mL, add 70μL of cell suspension to the wells of the 12-well plate cell plug (add 70μL of cell suspension to each well of the cell plug). When the cell confluence is about 90% (about 24h of culture), remove the cell plug and rinse it once with 2mL PBS.
[0070] 1.3 Administration
[0071] A blank group, LC2 sample group (2, 20 and 200 μg / mL) and fish skin collagen peptide (FCP, 200 μg / mL) group were set up, with three parallel controls in each group. 1 mL of DMEM medium containing 10% PBS (without serum) was added to the blank group, 1 mL of DMEM medium containing samples of different concentrations (sample concentrations were: 2, 20 and 200 μg / mL, without serum) was added to the LC2 sample group, and 1 mL of DMEM medium containing fish skin collagen peptide (200 μg / mL, without serum) was added to the FCP group, and the cells were placed in a cell culture incubator and incubated for 24 h.
[0072] 1.4 Calculation of cell migration rate
[0073] The scratch area of HaCaT cells in each group was recorded by taking photos at 0, 16 and 24 h after drug administration. The scratch area of cells was calculated using ImageJ, and the cell migration rate was calculated according to the following formula:
[0074]
[0075] 1.5 Statistical methods
[0076] The experimental results were summarized and statistically analyzed using GraphPad Prism 7 software. The experimental data were expressed as mean ± standard deviation (Mean ± SD). Compared with the cell migration rate of the blank group, P < 0.05 was statistically different, P < 0.01 was significantly statistically different, and P < 0.001 was extremely significantly statistically different.
[0077] 2 Experimental results
[0078] The effect of each group of treatments on HaCaT cell migration activity is shown in Table 3. The control sample fish skin collagen peptide has significant activity in promoting cell migration, and more than 80% of the scratches are covered after 200μg / mL FCP treatment for 24 hours. The experimental results show that LC2 also has significant activity in promoting cell migration (P<0.001). After 24 hours of treatment with 2-20μg / mL LC2, more than 75% of the scratches are covered; after 24 hours of treatment with a concentration of 200μg / mL LC2, the scratches are almost completely covered. Therefore, the hydrolyzed peptide disclosed in the present invention has the activity of promoting cell migration, which is the basis of physiological processes such as wound healing and angiogenesis, indicating that the hydrolyzed peptide can be used to prepare cosmetics, health foods, medical beauty products, and biomedical products.
[0079] Table 3 Activity of hydrolyzed peptides on HaCaT cell migration (Mean±SD, n=3)
[0080]
[0081] *: compared with the blank group, P<0.05; **: compared with the blank group, P<0.01; ***: compared with the blank group, P<0.001.
[0082] Example 4: Moisturizing and hydrating effects of hydrolyzed peptides
[0083] 1 Experimental methods
[0084] 1.1 Experimental Grouping
[0085] Volunteer recruitment: Volunteers who met the hydration and moisturizing efficacy test were recruited according to the standards in Table 4. A total of 23 people were recruited, including 5 males and 18 females with an average age of 29 years old. They signed informed consent forms and their information was registered.
[0086] Table 4 Volunteer recruitment criteria for hydration and moisturizing efficacy test
[0087]
[0088]
[0089] The experiment set up a blank group, a fish skin collagen peptide group (FCP, 200 μg / mL) and an LC1 sample group, and set two different concentrations (100 and 200 μg / mL), and each group was set up with 2 biological replicates.
[0090] 1.2 Hydrating and moisturizing effect experiment
[0091] The subjects should not use any products (cosmetics or topical drugs) on the forearm test site 2 to 3 days before the test, and should not come into contact with water 1 to 3 hours before the test. Before the test, wipe the inside of the forearms of both hands of the subjects clean with dry tissue paper.
[0092] Mark the measurement area on the inner side of the forearms of both hands of the subjects. The test area is 3cm×3cm, and the interval between each test area on the same arm is 1.5cm.
[0093] Before the test begins, the subjects sit quietly for 20 minutes in a room that meets the standards of an ambient temperature of 20-22°C and a humidity of 40%-60%. They are not allowed to drink water or other beverages. They expose their forearms in the test position and remain relaxed.
[0094] After adjusting the instrument according to the instruction manual of the capacitance method skin moisture meter, measure the initial value of each test area (before using the sample). Set up an experimental group, a control group and a blank control group, and evenly apply the test samples to the pre-marked test areas. 2h, 6h, and 8h after the sample is used, use the moisture meter again to measure the skin moisture content of the test area and the control area, and keep records. The same instrument is used for the test of the same subject and is completed by the same measurement personnel. Clean the measurement probe between two measurements.
[0095] 2 Experimental results
[0096] The effects of each group of treatments on the moisture content of human skin are shown in Table 5. Under natural conditions, the growth of human skin moisture shows a negative growth trend. The growth of human skin moisture in the hydrolyzed peptide LC1 group was higher than 6% in 2 to 8 hours, indicating that it can effectively replenish skin moisture and keep the skin moisturized. In this embodiment, when the concentration becomes higher, the hydrolyzed peptide LC1 exhibits stronger hydrating and moisturizing activity. In addition, fish collagen peptide also exhibits hydrating and moisturizing effects. Therefore, the hydrolyzed peptide disclosed in the present invention has hydrating and moisturizing effects, indicating that the hydrolyzed peptide can be used to prepare cosmetics, health products and medical beauty products.
[0097] Table 5 Effect of hydrolyzed peptides on human skin moisture content
[0098]
[0099]
[0100] Example 5: Antioxidant activity of hydrolyzed peptides
[0101] 1 Experimental methods
[0102] 1.1 Experimental Grouping
[0103] The experiment set up LC3 sample group, positive control group (positive drug glutathione GSH) and fish skin collagen peptide group (FCP group). The LC3 sample group was set at 10, 20, 30, 40 and 50g / L, a total of 5 test concentrations, the positive control group (GSH) and the control sample test concentration were 50g / L, and each group treatment was set up 3 biological replicates.
[0104] 1.2 Activity Detection
[0105] The scavenging abilities of the samples for DPPH free radical, ABTS free radical and hydroxyl free radical were determined and calculated according to the instructions of the respective kits.
[0106] 2 Experimental results
[0107] The antioxidant capacity data of each group of treatments are shown in Table 6. The scavenging rates of DPPH free radicals, ABTS free radicals and hydroxyl free radicals are effective indicators for measuring the antioxidant capacity of compounds. Glutathione (GSH) is a recognized antioxidant, and GSH can effectively scavenge DPPH free radicals, ABTS free radicals and hydroxyl free radicals, with scavenging rates of 46.99%, 37.08% and 43.42%, respectively. The hydrolyzed peptide LC3 has an antioxidant capacity similar to that of GSH, and can effectively scavenge DPPH free radicals, ABTS free radicals and hydroxyl free radicals. In this embodiment, when the concentration of LC3 is 50g / L, the scavenging rates of LC3 for DPPH free radicals, ABTS free radicals and hydroxyl free radicals reach the highest, which are 43.39%, 36.47% and 38.85%, respectively. In addition, FCP also has similar free radical scavenging activity. Therefore, the hydrolyzed peptide disclosed in the present invention has antioxidant activity, indicating that the hydrolyzed peptide can be used to prepare cosmetics, health products and medical beauty products.
[0108] Table 6 Free radical scavenging rate of hydrolyzed peptides (Mean±SD, n=3)
[0109]
[0110] Example 6: Anti-aging activity of hydrolyzed peptides
[0111] 1 Experimental methods
[0112] 1.1 Cell seeding
[0113] HSF cells in the logarithmic growth phase were taken at 2×10 5 Cells / well were seeded in 12-well plates.
[0114] 1.2 Experimental Grouping
[0115] The experiment set up a blank group, a model group, a positive drug group (0.2 μg / mL TGF-β1), a fish skin collagen peptide group (FCP, 100 μg / mL) and an LC2 sample group. At the same time, three different concentrations (1, 10 and 100 μg / mL) were set, and all experimental groups were set up with three biological replicates.
[0116] 1.3 Modeling
[0117] After 24 h of culture, the culture medium was aspirated, and 1 mL of PBS was added for rinsing. Then, 500 μL of PBS was added to each group of cell wells, and the above-mentioned well plate was placed in a UV cross-linking instrument for irradiation with a dose of 2J (the blank group was not irradiated with UVA, but was placed in a carbon dioxide incubator for 2 h). After the UV irradiation / culture, PBS was aspirated, and 500 μL of DMEM complete culture medium was added and placed in a carbon dioxide incubator for 2 h.
[0118] 1.4 Administration
[0119] After the end of experimental method 1.3, rinse once with 1 mL PBS, add 500 μL of drug-containing serum-free DMEM medium to each group, the concentration is as described in experimental method 1.2; the blank group and model group are replaced by 500 μL of drug-free serum-free DMEM medium. After incubating the well plate in a carbon dioxide incubator for 24 hours, collect the cell supernatant and store it at -20℃ for testing.
[0120] 1.5 Detection
[0121] Human collagen α1 (Col-α1) and human hyaluronic acid (HA) were detected according to the instructions in the ELISA kit.
[0122] 1.6 Statistical methods
[0123] The experimental results were summarized and statistically analyzed using GraphPad Prism 7 software. The final results of the experiment were expressed as mean ± standard deviation (Mean ± SD). Compared with the model group, P < 0.05 was statistically different, P < 0.01 was significantly statistically different, and P < 0.001 was extremely significantly statistically different.
[0124] 2 Experimental results
[0125] The effects of each treatment group on the anti-aging activity of HSF cells are shown in Table 7. The positive drug TGF-β1 has significant anti-aging activity. At a concentration of 0.2 μg / mL, it can significantly inhibit the reduction of Col-α1 and HA content in HSF cells. At the same time, LC2 also showed significant anti-aging activity. At a concentration of 1-100 μg / mL, it can inhibit the reduction of Col-α1 and HA content in HSF cells to varying degrees. At the same time, the anti-aging activity of LC2 is basically equivalent to that of FCP.
[0126] Collagen is a very important protein in the body, mainly present in connective tissue, with strong stretching ability, so that the skin maintains elasticity, and the aging and loss of collagen will cause wrinkles on the skin. Hyaluronic acid is widely present in the body and is one of the main components of tissues, providing structural support for cells. Hyaluronic acid has a significant ability to lock water. With the increase of age, hyaluronic acid is gradually lost, the moisture of the skin decreases, and the elasticity is lost, which leads to signs of aging of the skin. Therefore, the content of collagen and hyaluronic acid is an important indicator for measuring anti-aging activities. In summary, the hydrolyzed peptides disclosed in the present invention have the activity of cell anti-aging, indicating that the hydrolyzed peptides can be used to prepare cosmetics, health products, and medical beauty products.
[0127] Table 7 Anti-aging activity of hydrolyzed peptides on HSF cells (Mean±SD, n=3)
[0128]
[0129] *: compared with the blank group, P<0.05; **: compared with the blank group, P<0.01.
[0130] Example 7: Repair activity of hydrolyzed peptides
[0131] 1 Experimental methods
[0132] 1.1 Experimental Grouping
[0133] The experiment set up a normal group, a tail-cut group, a fish skin collagen peptide group (FCP, 100 μg / mL) and an LC4 sample group, and set three different concentrations (25, 50 and 100 μg / mL).
[0134] 1.2 Zebrafish tail fin regeneration experiment
[0135] 90 6-month-old wild-type zebrafish of the ab strain were randomly divided into 6 groups according to the experimental method 1.1, with 15 fish in each group. Except for the normal group, the tail fin was transected under a stereoscope after 0.02% tricaine anesthesia, and the corresponding concentrations of FCP and LC4 were added to the culture medium to continue feeding according to the experimental method 1.1. The tail fin recovery was recorded by taking photos on the 3rd and 7th days after tail amputation, and the tail fin area was calculated every day using Image J software. The recovery rate (P n ), where A0 is the tail fin area of the normal group, A M is the tail fin area of the broken tail group, A T is the tail fin area of the treatment group.
[0136]
[0137] 1.3 Statistical methods
[0138] The experimental results were summarized and statistically analyzed using GraphPad Prism 7 software. The final results of the experiment were expressed as mean ± standard deviation (Mean ± SD). Compared with the model group data, P < 0.05 was considered statistically significant.
[0139] 2 Experimental results
[0140] The effects of each group of treatments on the recovery of the zebrafish tail fin are shown in Table 8 below. Under natural conditions, the zebrafish tail fin has good self-repair ability, and the tail fin has recovered nearly 50% one week after the tail was cut off (model group). Hydrolyzed collagen peptide LC4 can significantly accelerate the recovery of the zebrafish tail fin. After 3 days of treatment with 100 μg / mL LC4, the zebrafish tail fin has recovered 24.17%. After 7 days of treatment, the zebrafish tail fin has recovered 63.06%. In addition, fish collagen peptides also show a certain accelerated repair effect. Therefore, the hydrolyzed collagen peptides disclosed in the present invention have the activity of promoting the repair of zebrafish tail fins, indicating that the hydrolyzed peptides can be used to prepare cosmetics, medical beauty products, health products, biomedical products, spongy materials, fibers, gel-like materials and membrane materials.
[0141] Table 8 Effect of hydrolyzed collagen peptide on the recovery rate of zebrafish tail fin (Mean±SD, n=15)
[0142]
[0143] *: Compared with the blank group, P<0.05.
Claims
1. A hydrolyzed peptide of recombinant collagen, selected from: Hydrolyzed peptide LC1, which is obtained by mixing recombinant collagen-like protein with an amino acid sequence as shown in SEQ ID NO: 1 and intracellular protease at a protein mass concentration ratio of 1:100, hydrolyzing at 28°C, pH=7.0 in 50 mM Tris-HCl for 16 h, and inactivating at 95°C; or hydrolyzed peptide LC2, which is obtained by mixing recombinant collagen-like protein with an amino acid sequence as shown in SEQ ID NO: 1 and intracellular protease at a protein mass concentration ratio of 1:500, hydrolyzing at 30° C., pH=8.0 in 100 mM Tris-HCl for 12 h, and inactivating at 95° C.; or hydrolyzed peptide LC3, which is obtained by mixing recombinant collagen-like protein with an amino acid sequence as shown in SEQ ID NO: 1 and intracellular protease at a protein mass concentration ratio of 1:800, hydrolyzing at 37° C., 100 mM Tris-HCl, pH=8.5 for 8 h, and inactivating at 95° C.; or hydrolyzed peptide LC4, which is obtained by mixing a recombinant collagen-like protein with an amino acid sequence as shown in SEQ ID NO: 1 and an intracellular protease at a protein mass concentration ratio of 1:1500, hydrolyzing at 42°C, 50 mM Tris-HCl, pH=7.5 for 2 h, and inactivating at 95°C; The intracellular protease is lysyl endo-lysine.
2. Use of the hydrolyzed peptide according to claim 1 in the preparation of anti-aging products, repair products, hydrating and moisturizing products or antioxidant products.
3. Use of the hydrolyzed peptide according to claim 1 in the preparation of health products, cosmetics, and medical beauty products.
4. A composition comprising the hydrolyzed peptide according to claim 1. The composition according to claim 4 , which is a health product, a cosmetic or a medical beauty product.
6. The composition according to claim 4, which is an anti-aging product, a repair product, a hydrating and moisturizing product or an antioxidant product.
7. Use of a recombinant collagen-like protein having an amino acid sequence as shown in SEQ ID NO: 1 for preparing hydrolyzed peptides under the action of lysyl endonuclease.
